Beta-Testing of New HealthTab™ System in First Shoppers Drug Mart® Pharmacy Performs Well, Shows Strong Patient Demand
July 19 2021 - 08:33AM
AVRICORE HEALTH INC. (TSXV: AVCR) (the
"
Company" or “
AVCR”) announces
that patient testing has begun on the first deployment of the new
HealthTab™-integrated Afinion 2™ analyzers in the initial Shoppers
Drug Mart® pharmacy location as part of its previously announced
effort to screen for diabetes and cardiovascular disease,
demonstrating strong demand, smooth workflow, and reliable system
operations.
To prepare for the full public launch of the program, announced
in May of this year, a first store was selected to receive the
system to begin beta-testing HealthTab™’s systems, including the
first patient tests. This work has successfully demonstrated that
the very first installation of HealthTab™ with the Afinion 2™
analyzers is ready for prime-time, with HealthTab™ and the
instruments performing well.
So successful was the initial week that more than 90 patients
were tested and over 600 results were reported over the initial
trial period between July 5 – July 18 at this single location.
“I’m so excited to have HealthTab™ in my store
because I believe this is going to demonstrate a new and better way
to do pharmacy practice,” said Mohamed Adel Elsabakhawi, the first
Pharmacist and Associate Owner of a Shoppers Drug Mart located in
Mississauga, Ontario to operate the platform. “This is really
profound because having access to lab-accurate results at our
fingertips means we can better help family physicians by conducting
regular follow up using advanced diagnostics with our diabetic and
cardiovascular patients more effectively.”
In May 2021, HealthTab™ signed a Master Agreement with Shoppers
Drug Mart Inc. to pilot the HealthTab™ platform. This agreement
allows patients access to point-of-care blood screening and
health-data management for potential risks for developing diabetes
and cardiovascular conditions through the HealthTab™-integrated
Afinion 2™ analyzers by Abbott Rapid Diagnostics.
All locations have now received their HealthTab™ systems and are
being prepared to be online as soon. To find a location near you,
please visit: healthtab.com/locations
About HealthTab™ +
RASTR
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19. The HealthTab™ network model is unlike anything
in pharmacy today. It gives knowledgeable and trusted pharmacists a
greater role in primary care delivery, while empowering patients to
take more control of their health. It also reduces costs and
waiting times and provides many potential revenue streams including
equipment leasing & consumables, direct access testing, disease
prevention & management programs, sponsored health programs,
decentralized clinical trials, real world data (RWD) sets, and
third-party app integration through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service
innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™ (a wholly owned subsidiary), its mission is to
make actionable health information more accessible to everyone by
creating the world’s largest network of rapid testing devices in
community pharmacies.
Contact:
Avricore Health
Inc. Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com www.avricorehealth.com
Cautionary Note Regarding Forward-Looking
Statements Information in this press release that involves
Avricore Health's expectations, plans, intentions or strategies
regarding the future are forward-looking statements that are not
facts and involve a number of risks and uncertainties. Avricore
Health generally uses words such as "outlook," "will," "could,"
"would," "might," "remains," "to be," "plans," "believes," "may,"
"expects," "intends," "anticipates," "estimate," "future,"
"positioned," "potential," "project," "remain," "scheduled," "set
to," "subject to," "upcoming," and similar expressions to help
identify forward-looking statements. In this press release,
forward-looking statements include statements regarding: the
completion of the placement and the expected timing thereof and the
Company's expected use of proceeds from the placement; the unique
features that the HealthTab™ platform offers to pharmacists and
patients. Forward-looking statements reflect the then-current
expectations, beliefs, assumptions, estimates and forecasts of
Avricore Health's management. The forward-looking statements in
this press release are based upon information available to Avricore
Health as of the date of this press release. Forward-looking
statements believed to be true when made may ultimately prove to be
incorrect. These statements are not guarantees of the future
performance of Avricore Health and are subject to a number of
risks, uncertainties and other factors, some of which are beyond
its control and may cause actual results to differ materially from
current expectations, including without limitation: failure to meet
regulatory requirements; changes in the market; potential downturns
in economic conditions; and other risk factors described in
Avricore's public filings. These forward-looking statements speak
only as of the date on which they are made, and the Company
undertakes no obligation to update them publicly to reflect new
information or the occurrence of future events or circumstances,
unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Mar 2023 to Mar 2024